Astrea Bioseparations introduces Nereus LentiHERO, a convenient solution for the purification of lentiviral vectors

Astrea Bioseparations introduces Nereus LentiHERO, a convenient solution for the purification of lentiviral vectors

Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools that support the development of next-generation therapeutics, today announced the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology. This novel solution contains AstreAdept™, the company's proprietary nanofiber material, and addresses the challenges associated with cleaning the large and fragile products used in cell and gene therapy.

“We believe AstreAdept will be a game-changer,” said Terry Pizzie, CEO of Astrea Bioseparations.

Our approach was to rapidly develop and integrate this material into the Nereus LentiHERO, a simple, convenient device that radically changes the way lentiviruses can be purified [in terms of speed, recovery, and efficiency].” He added: “This launch also sets the stage for a future where cutting-edge therapies can get into the hands of patients faster and more cost-effectively than ever before.”

Despite the significant potential of LVV therapeutics, the pace of development has been slow due to the lack of suitable platforms and users have had to rely on outdated and inefficient devices. To overcome these obstacles, Astrea Bio develops uniquely designed products that are easier to use than previous approaches.

“High yields coupled with fast cleaning are now possible through the use of AstreAdept,” explained Mr. Pizzie.

AstreAdept is a proprietary bioseparation material that utilizes state-of-the-art nanofiber technology, enabling biologics manufacturers to shorten process times, increase process efficiency, reduce buffer consumption and therefore reduce waste treatment costs. This enables more environmentally friendly, faster and more cost-effective workflows in bioprocessing.

Astrea Bio has been developing purification and separation technologies for more than 30 years and uses multiple products to produce FDA-approved treatments. Nereus LentiHERO is the first tool in the company's rapidly growing toolbox of purpose-built, next-generation solutions for the development and manufacturing of cell and gene therapies.

Further information about Astrea Bioseparations can be found at: https://www.astreabioseparations.com/